Articles from Revvity

Revvity, Inc. (NYSERVTY) today reported financial results for the fourth quarter and full year ended December 29, 2024.

The Board of Directors of Revvity (NYSERVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on May 9, 2025 to all shareholders of record at the close of business on April 18, 2025.

Revvity, Inc. (NYSERVTY), today announced a strategic agreement to commercialize an in vitro diagnostic (IVD) workflow solution for neonatal sequencing, co-developed with Element Biosciences, Inc., a life science company democratizing access to advanced DNA and multi-omic sequencing solutions. This initiative builds upon Revvity's recent introduction of an automated next-generation sequencing (NGS) workflow for newborn sequencing research and strengthens Element’s momentum towards regulatory approval of the benchtop AVITI™ sequencing system.

Revvity, Inc. is set to unveil its groundbreaking new Phenologic.AI™ software at SLAS2025 in San Diego, January 27-29. Designed to redefine cellular imaging workflows for Revvity’s Harmony™ and Signals Image Artist™ software packages, the Phenologic.AI software leverages pre-trained deep-learning models to analyze brightfield images, providing an additional multiplexing channel and streamlined workflows for live cell analysis. This significant advancement expands the possibilities for understanding cellular behaviors and disease mechanisms. The Phenologic.AI offering provides scalable, efficient, and objective analysis and can be integrated with Revvity Signals Research Suite™ to provide more in-depth data analytics.

Revvity, Inc. (NYSERVTY), today announced that it will release its fourth quarter and full year 2024 financial results prior to market open on Friday, January 31, 2025. The Company will host a conference call the same day at 8:00 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call.

Revvity, Inc. (NYSERVTY), today announced that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for EUROIMMUN’s automated chemiluminescence-based immunoassay (ChLIA) test for free testosterone. This innovative test is the first of its kind to receive FDA clearance for direct quantitative measurement of free testosterone levels, marking a significant advancement in diagnostic capabilities for androgen disorders.

Revvity, Inc. (NYSERVTY) will present at the 43rd annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 8:15 a.m. PT in San Francisco, CA.

Revvity, Inc. (NYSERVTY), today announced an expansion of its work with Genomics England that leverages both organizations' expertise and resources to advance critical genomic initiatives across the United Kingdom. Building on the parties’ long and productive work history, this advanced collaboration is dedicated to accelerating Genomics England’s renowned research programs, supporting diverse areas in genomics, and fostering talent in innovative healthcare fields.

Revvity, Inc. (NYSERVTY), will present at the 7th Annual Evercore ISI HealthCONx Conference on Tuesday, December 3, 2024, at 8:20 a.m. ET in Coral Gables, FL.

Revvity, Inc. (NYSERVTY), today announced it will host an Investor Day on Thursday, November 21, 2024 at 9:00 a.m. PT which will feature presentations by members of Revvity’s senior management team on the Company’s key business initiatives, operational achievements and future financial outlook.

Revvity, Inc. (NYSERVTY), today reported financial results for the third quarter ended September 29, 2024.

The Board of Directors of Revvity, Inc. (NYSERVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on February 7, 2025 to all shareholders of record at the close of business on January 17, 2025.

Revvity, Inc. (NYSERVTY) today announced the launch of Revvity Transcribe AI, an innovative optical character recognition (OCR) service designed to convert handwritten text on test request forms into a digitized format. This cutting-edge solution is now available to clinical laboratories, aiming to streamline workflows and reduce manual data entry tasks.

Revvity, Inc. (NYSERVTY) today unveils its annual Impact Report, a declaration of the Company’s sustainability, social and governance strategy, initiatives and performance. The report showcases Revvity’s continued evolution and strengthened commitments to creating a lasting, positive impact on the world.

Revvity, Inc. (NYSERVTY), today announced that it will release its third quarter 2024 financial results prior to market open on Monday, November 4, 2024. The Company will host a conference call the same day at 8:00 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call.

Revvity, Inc. (NYSERVTY), announced today the launch of the in-vitro diagnostic EURORealTimeTM APOE assay in European countries that accept the CE mark, which will enable accurate genotyping of the APOE gene. APOE genotyping is valuable to assess a patient’s risk for side effects prior to the start of an anti-amyloid (beta) therapy in Alzheimer’s disease.

Revvity, Inc. (NYSERVTY), today announced it will present at the following investor conferences in September 2024:

Revvity, Inc. (NYSERVTY), today reported financial results for the second quarter ended June 30, 2024.

The Board of Directors of Revvity (NYSERVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on November 8, 2024 to all shareholders of record at the close of business on October 18, 2024.

Revvity, Inc. (NYSERVTY), today announced that it will release its second quarter 2024 financial results prior to market open on Monday, July 29, 2024. The Company will host a conference call the same day at 8:00 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call.

Revvity, Inc. (NYSERVTY) will present at the 45th Annual Goldman Sachs Global Healthcare Conference on Monday, June 10, 2024 at 8:00 a.m. ET in Miami, FL.

Revvity, Inc. (NYSERVTY), today reported financial results for the first quarter ended March 31, 2024.

The Board of Directors of Revvity (NYSERVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on August 9, 2024 to all shareholders of record at the close of business on July 19, 2024.

Revvity, Inc. (NYSERVTY) will present at the BofA Securities 2024 Health Care Conference on Tuesday, May 14, 2024 at 8:40 a.m. PT in Las Vegas, NV.

Revvity, Inc. (NYSERVTY) today announced the launch of the Auto-Pure 2400 liquid handler from Allsheng for use with the T-SPOT.TB test. The Auto-Pure 2400 platform is easy to use and designed to provide efficient workflows in the lab. When the accuracy of the T-SPOT.TB test is combined with the efficiency of the Auto-Pure 2400 system, labs, clinicians and ultimately patients, benefit from the resultant powerful solution.

Today, Revvity, Inc. (NYSERVTY) announced that its software and informatics division, Revvity Signals, will launch Signals SynergyTM, a software solution designed to drive greater collaboration, project management, and data exchange between pharmaceutical and biotechnology sponsors with their external contract partners.

Revvity, Inc. (NYSERVTY), today announced that it will release its first quarter 2024 financial results prior to market open on Monday, April 29, 2024. The Company will host a conference call the same day at 8:00 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call.

Today, Revvity, Inc. (NYSERVTY) announced that the Massachusetts Superior Court has granted a preliminary injunction compelling Cloud Software Group (CSG) to comply with its contractual obligations under its strategic partner agreements with Revvity, including an order to cease all marketing, selling and support activities in Revvity’s exclusive markets and to continue delivering maintenance services to Revvity in relation to its Spotfire® software.

Today, Revvity, Inc. (NYSERVTY) announced that it has filed a complaint against Cloud Software Group (CSG) in Massachusetts Superior Court and requested injunctive relief to enforce Revvity’s rights and CSG’s obligations as a strategic partner.

Today, Revvity, Inc. (NYSERVTY) announced that its software and informatics division, Revvity Signals Software, is introducing the new Signals ChemDraw® offering, the latest advancement in the Revvity Signals Software portfolio. This innovative chemistry suite is set to transform the way researchers in the pharmaceutical and non-pharmaceutical chemical industries, as well as academia, develop and communicate complex chemical concepts and collaborate across disciplines.

Revvity, Inc. today announced the introduction of a flexible end-to-end workflow solution for newborn research, enabling users to utilize different instruments, reagents and databases based on a lab’s needs.

Revvity, Inc. (NYSERVTY) today announced it will present at the following investor conferences in February and March 2024:

Today, Revvity, Inc. (NYSERVTY) announced that its software and informatics division, Revvity Signals, is unveiling the Signals ClinicalTM solution, a software-as-a-service (SaaS), end-to-end clinical data science platform designed to centralize all clinical trial data, providing fast, actionable insights for quicker clinical decisions and accelerated market delivery of therapeutics. This state-of-the-art solution, when integrated with enterprise-class Spotfire visual analytics, has the potential to redefine how the pharmaceutical, biotechnology, and contract research industries approach clinical trial data, offering an unprecedented level of access and insight to drive forward clinical development and therapeutic innovations.

Revvity, Inc. is set to boldly unveil its new branding while showcasing more than 40 products from its life sciences and diagnostics portfolio at SLAS2024 to be held in Boston from February 3-7 in booth #408. The latest product introductions and technological synergies across its portfolio, which are designed to spur scientific advancement and drive efficiencies in drug development – with a special emphasis on the innovation and discovery phase - will be featured throughout at its exhibit and in several talks and poster presentations.

Revvity, Inc. (NYSERVTY), today reported financial results for the fourth quarter and full year ended December 31, 2023.

Revvity, Inc. (NYSERVTY), today announced that Sophie Vandebroek and Michael Klobuchar have been elected to its board of directors, effective February 1, 2024.

The Board of Directors of Revvity, Inc. (NYSERVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on May 10, 2024 to all shareholders of record at the close of business on April 19, 2024.

Revvity, Inc. (NYSERVTY) today announced that it will release its fourth quarter and full year 2023 financial results prior to market open on Thursday, February 1, 2024. The Company will host a conference call the same day at 8:00 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call.

Revvity, Inc. (NYSERVTY) will present at the 42nd annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024 at 10:30 a.m. PT in San Francisco, CA.

Today, Revvity, Inc., announced the launch of its EONIS™ Q system, a CE-IVD declared platform enabling laboratories in countries that accept the CE marking to adopt molecular testing for spinal muscular atrophy (SMA) and severe combined immunodeficiency (SCID) in newborns.

Revvity, Inc. (NYSERVTY) will present at the 6th Annual Evercore ISI HealthCONx Conference on Tuesday, November 28, 2023 at 9:10 a.m. ET in Miami, FL.

Revvity, Inc. (NYSERVTY), today reported financial results for the third quarter ended October 1, 2023.

The Board of Directors of Revvity (NYSERVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on February 9, 2024 to all shareholders of record at the close of business on January 19, 2024.

Revvity, Inc. (NYSERVTY) today unveils its inaugural 2023 Environmental, Social and Governance (ESG) Report. An in-depth overview of the Company’s ESG strategy, initiatives and performance, the report showcases the Company’s deepening commitment to driving more sustainable solutions, along with a culture of transparency, empowerment and inclusivity.

Revvity, Inc. and Element Biosciences, Inc., a developer of the AVITI™ System, an innovative and emerging genomic sequencing platform, today announced a collaboration to introduce workflow solutions that save time and effort required for genomic analysis of samples.

Revvity, Inc. (NYSERVTY), today announced that it will release its third quarter 2023 financial results prior to market open on Monday, October 30, 2023. The Company will host a conference call the same day at 8:00 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call.

Revvity, Inc., (NYSERVTY) today unveils its groundbreaking Pin-point™ base editing platform reagents, providing researchers with unparalleled access to implement the advanced gene editing technique in their preclinical laboratories. Base editing represents a pivotal advancement in CRISPR gene editing, providing the capability for complex and safe multi-gene editing, which can result in enhanced functional genomics insights for optimizing drug development, as well as streamlining cell line and cell therapy development and manufacturing. The Pin-point platform is one of the few established base editing technologies currently being employed in clinical settings, positioning it as both a discovery and therapeutic tool.

Revvity, Inc. (NYSERVTY) today debuts its enhanced imaging portfolio designed to drive innovation across diverse applications in preclinical research with the launch of three systems. These new innovations include the next-generation IVIS® Spectrum 2 and the IVIS SpectrumCT 2 imaging systems, further elevating versatility and sensitivity standards in in vivo optical imaging. Also launching is the QuantumTM GX3 microCT structural imaging solution with increased resolution and speed for both in vivo and ex vivo imaging, designed to facilitate researchers studying disease biology or evaluating and fast-tracking therapeutic candidates. And making its global debut is the Vega® ultrasound system, originally launched in North America in 2022. These cutting-edge technologies will be showcased at the World Molecular Imaging Congress (WMIC) being held September 5-9, in Prague, Czech Republic.

Revvity, Inc. (NYSERVTY) today announced it will present at the 2023 Wells Fargo Healthcare Conference, the Baird 2023 Global Healthcare Conference and the Bank of America European Healthcare Conference.

Revvity, Inc. (NYSERVTY), today reported financial results for the second quarter ended July 2, 2023.

Today, Revvity announced that its Revvity Signals Software business has entered into a strategic relationship with Scitara – a leading global provider of cloud-based solutions for the scientific industry. Together, the companies will transform the way R&D teams work across the biotech, pharmaceutical and chemical industries with technology that accelerates digital transformation in the lab environment. Revvity Signals Software has added a new “Signals Digital Lab Exchange” offering to its product portfolio that combines Scitara’s DLXTM technology with Revvity’s existing Signals platform to accelerate the flow of scientific data to-and-from the Revvity Signals Research Suite.

The Board of Directors of Revvity (NYSERVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on November 10, 2023 to all shareholders of record at the close of business on October 20, 2023.

Revvity (NYSERVTY), today announced the launch of the Fontus™ Automated Liquid Handling Workstation, a next-generation liquid handler incorporating the best technologies from Revvity’s existing platforms, designed to deliver easier and faster workflows which enable better results for next generation sequencing (NGS) and diagnostic research applications.

Revvity (NYSERVTY), today announced that it will release its second quarter 2023 financial results prior to market open on Tuesday, August 1, 2023. The Company will host a conference call the same day at 8:00 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call.

Today, in collaboration with single cell genomics company, Honeycomb Biotechnologies (“Honeycomb”), Revvity (NYSERVTY) announced the launch of a suite of new solutions and services that expand the frontiers of single cell biology: the HIVE™ CLX Single-Cell RNAseq Solution, BeeNetPLUS analysis workflow, and for single cell researchers based in the United States, a new HIVE CLX Service offering.

Revvity, Inc. (NYSERVTY), announced today that its EUROIMMUN business has launched the UNIQO 160 (CE-IVDR), an automated indirect immunofluorescence test (IIFT) system for autoimmune disease diagnostics. Now available in countries accepting the CE mark, this all-in-one solution increases the efficiency of the entire IIFT process, encompassing sample preparation, incubation, washing and mounting of slides as well as image acquisition and analysis.

Today, Revvity, Inc. (NYSERVTY), announced the launch of its Signals Research Suite, a unified, cloud-native SaaS platform that drives scientific collaboration across R&D disciplines from drug discovery to specialty chemicals material development. The new solution from Revvity Signals Software, the software and informatics arm of Revvity, is available worldwide. It integrates the Revvity Signals Notebook, VitroVivo and Inventa applications into a single, robust solution that supports the entire drug development process, from early research and in vitro testing and safety to early development as well as specialty chemicals new product development.

Revvity, Inc. (NYSERVTY) will present at the 44th Annual Goldman Sachs Global Healthcare Conference on Tuesday, June 13, 2023 at 8:40 a.m. PT at the Waldorf Astoria Monarch Beach Resort & Club in Dana Point, CA.

Revvity, Inc. (NYSERVTY), today announced a new license agreement with AstraZeneca (LSE/STO/Nasdaq: AZN) for the technology underlying its Pin-point™ base editing system, a next-generation modular gene editing platform with a strong safety profile.